logo-loader
viewCytoDyn Inc.

CytoDyn CEO calls Citron Research report 'false', updates on coronavirus clinical trials

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan addressed the recent report published by short seller Citron Research, entitled "SEC must immediately halt this stock promotion scheme."

What's more, Pourhassan talked about the firm's two US-based coronavirus clinical trials, and its anticipated Phase 3 clinical trial with the NIH in Mexico.

Quick facts: CytoDyn Inc.

Price: 4.81 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $2.5 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn’s Leronlimab receives positive DSMC recommendation in ongoing Phase...

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan and Chief Scientific Advisor Dr Jay Lalezari joined Steve Darling from Proactive with news the company has had results from an independent Data Safety Monitoring Committee who completed its first safety review of the ongoing Phase 3 clinical trial of...

14 hours, 13 minutes ago

2 min read